X-ELIO, a global leader in the renewable energy sector, and the Net Zero Consortium for Buyers (NZCB) have announced the signing of six virtual power purchase agreements (PPAs) for a combined total ...

Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

February 2024 saw Cisco sign a 15-year vPPA to offtake from a 37MW solar farm in Spain developed by IGNIS. The farm is set to ...

Six PPAs to achieve NZCB's sustainability goals Cisco Systems, Biogen, IDEXX Laboratories, and Waters Corporation have signed multiple PPAs with X-ELIO, further reinforcing their commitment to ...

Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...

Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...

BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.

Biogen acquired HI-Bio in July 2024 ... AMR in kidney transplant is caused by the immune system recognizing the donor kidney as foreign. This can result in antibodies being generated against ...

Results saw all 24 healthy volunteers who made it to the 72-week mark still had effective levels of dMAb in their systems.